Global Lanreotide Drugs Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Lanreotide Drugs Market Insights, Forecast to 2034
Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome
Global Lanreotide Drugs market is expected to reach to US$ 1415 million in 2024, with a positive growth of %, compared with US$ 1401 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Lanreotide Drugs industry is evaluated to reach US$ 1506.5 million in 2029. The CAGR will be 1.1% during 2024 to 2029.
Lanreotide is a somatostatin analog primarily used to treat acromegaly and neuroendocrine tumors. Its efficacy in controlling hormone secretion and tumor growth has driven market growth. The rising prevalence of acromegaly and neuroendocrine tumors, coupled with the drug's extended duration of action, contributes to its popularity. However, competition from other somatostatin analogs and the need for individualized treatment plans may pose challenges. The market is relatively small compared to other therapeutic areas. Despite challenges, the Lanreotide market presents potential for expansion as healthcare providers prioritize personalized and targeted therapies for acromegaly and neuroendocrine tumors, creating opportunities for further development and investment.
Report Covers
This report presents an overview of global Lanreotide Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Lanreotide Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
IPSEN
Segment by Type
60 mg
90 mg
120 mg
Hospital
Pharmacy
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
UK
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Lanreotide Drugs plant distribution, commercial date of Lanreotide Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Lanreotide Drugs introduction, etc. Lanreotide Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Lanreotide Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Lanreotide Drugs market is expected to reach to US$ 1415 million in 2024, with a positive growth of %, compared with US$ 1401 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Lanreotide Drugs industry is evaluated to reach US$ 1506.5 million in 2029. The CAGR will be 1.1% during 2024 to 2029.
Lanreotide is a somatostatin analog primarily used to treat acromegaly and neuroendocrine tumors. Its efficacy in controlling hormone secretion and tumor growth has driven market growth. The rising prevalence of acromegaly and neuroendocrine tumors, coupled with the drug's extended duration of action, contributes to its popularity. However, competition from other somatostatin analogs and the need for individualized treatment plans may pose challenges. The market is relatively small compared to other therapeutic areas. Despite challenges, the Lanreotide market presents potential for expansion as healthcare providers prioritize personalized and targeted therapies for acromegaly and neuroendocrine tumors, creating opportunities for further development and investment.
Report Covers
This report presents an overview of global Lanreotide Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Lanreotide Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
IPSEN
Segment by Type
60 mg
90 mg
120 mg
Segment by Application
Hospital
Pharmacy
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
UK
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Lanreotide Drugs plant distribution, commercial date of Lanreotide Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Lanreotide Drugs introduction, etc. Lanreotide Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Lanreotide Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices